In vivo measurement of somatodendritic release of dopamine in the ventral tegmental area by Kita, Justin M. et al.
In vivo measurement of somatodendritic release of dopamine in
the ventral tegmental area
Justin M. Kita, Brian M. Kile, Lauren E. Parker, and R. Mark Wightman'
Department of Chemistry and Neuroscience Center, University of North Carolina, Chapel Hill, NC
27599-3290, USA,
Abstract
The ventral tegmental area (VTA), the locus of mesolimbic dopamine cell bodies, contains
dopamine. Experiments in brain slices have demonstrated that VTA dopamine can be released by
local electrical stimulation. Measurements with both push-pull cannula and microdialysis in intact
animals have also obtained evidence for releasable dopamine. Here we demonstrate that dopamine
release in the VTA can be evoked by remote stimulations of the medial forebrain bundle (MFB) in
the anesthetized rat. In initial experiments, the MFB was electrically stimulated while a carbon-
fiber electrode was lowered to the VTA, with recording by fast-scan cyclic voltammetry. While
release was not observed with the carbon fiber 4 to 6 mm below dura, a voltammetric response
was observed a t 6-8 mm below dura, but the voltammogram was poorly defined. At lower depths,
in the VTA, dopamine release was evoked. Immunohistochemistry experiments with antibodies
for tyrosine hydroxylase (TH) confirmed that dopamine processes were primarily found below 8
mm. Similarly, tissue content determined by liquid chromatography revealed serotonin but not
dopamine dorsal to 8 mm with both dopamine and serotonin at lower depths. Evaluation of the
VTA signal by pharmacological means showed that it increased with inhibitors of dopamine
uptake, but release was not altered by D2 agents. Dopamine release in the VTA was frequency
dependent and could be exhausted by stimulations longer than 5 s. Thus, VTA dopamine release
can be evoked in vivo by remote stimulations and it resembles release in terminal regions,
possessing a similar uptake mechanism and a finite releasable storage pool.
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The mesolimbic dopamine pathway projects from the ventral tegmental area (VTA) to the
nucleus accumbens and plays an important role in reward processing (Pan et al., 2005). It
runs parallel to another dopaminergic pathway, the nigrostriatal pathway, which regulates
locomotion and originates in the substantia nigra (SN). Dopamine release at the terminals of
both of these pathways has been extensively characterized. Terminal release is evoked by
action potentials, is highly regulated, and has a release capacity that is regulated by
dopamine stores in the active pool (Garris et al., 1993; Montague et al., 2004; Nicolaysen et
al., 1988). Following release, dopamine is cleared from the extracellular space by the
dopamine transporter (DAT), which transports it back into the neuron (Gainetdinov and
Caron, 2003). Because uptake is time dependent, whereas release is dependent on the
frequency of action potentials, dopamine overflow into the extracellular space is highly
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dependent on the frequency of action potentials. At high frequencies, uptake has little time
between pulses to sequester dopamine leading to greater overflow than at low frequencies
(Heien and Wightman, 2006; Wightman et al., 1988). As well as interacting with
postsynaptic receptors, dopamine binds to presynaptic autoreceptors that serve to inhibit
subsequent dopamine release (Garris et al., 2003; Phillips et al., 2002).
Dopamine is also stored in the dendrites of the SN and VTA (Bjorklund and Lindvall, 1975;
Cuello and Kelly, 1977). In the SN, Ca2+ dependent somatodendritic dopamine release was
first reported in brain slices (Geffen et al., 1976). This finding was confirmed by in vivo
measurement with a push-pull canula (Cheramy et al., 1981). Subsequent microdialysis
studies also demonstrated dopamine release in the VTA (Kalivas and Duffy, 1988).
Voltammetric measurements in VTA containing slices from guinea pig brain (Rice et al.,
1994), from rat (Iravani et al., 1996), and from mouse (John et al., 2006) also confirm
somatodendritic dopamine release evoked by local electrical stimulation. While dopamine
release was suggested to occur via reverse transport via the DAT (Falkenburger et al., 2001),
further research has shown that dendritic DA release is exocytotic in both the SN and VTA
(Chen and Rice, 2001; John and Jones, 2006). Somatodendritic dopamine release has a
presynaptic regulatory role as well as a postsynaptic role (Beckstead et al., 2007; Beckstead
et al., 2004), although it does not appear to play a role in regulating release in the VTA
(Cragg and Greenfield, 1997).
While neurons normally transmit action potentials from the cell bodies to the terminals, it
has been demonstrated that midbrain dopaminergic neurons can also backpropagate action
potentials (Gentet and Williams, 2007; Hausser et al., 1995) to the dendritic field. In this
work we have tested the hypothesis that back-propagation of action potentials in
dopaminergic neurons can evoke dopamine release. To achieve this goal, a stimulating
electrode was lowered in an anesthetized rat to the level of the MFB, and a carbon-fiber
microelectrode was placed in the VTA. Dopamine release in the VTA was measured during
stimulations with fast-scan cyclic voltammetry (Robinson et al., 2008). The stimulated
release of dopamine resembled its evoked release in terminal regions except it was lower,




Male Sprague-Dawley rats (225-350g; Charles River, Wilmington, MA) were anesthetized
with urethane (1.5 g/kg, i.p.) and placed in a stereotaxic frame (Kopf, Tujunga, CA). A
heating pad (Harvard Apparatus, Holliston, MA) maintained a constant body temperature of
37°C. Holes were drilled in the skull for the working, reference, and stimulation electrodes
at coordinates selected from a rat brain atlas (Paxinos and Watson, 1986). A Ag/AgCl
reference was inserted in the contralateral region of the brain.
Electrochemistry
Cylindrical carbon fiber microelectrodes were prepared using T650 carbon fibers (3 μm
radius, Amoco) and encased in glass capillaries (A-M Systems, Sequim, WA) and pulled
with a micropipette puller (Narashige, East Meadow, NY). The protruding fiber was then cut
to a length of 50-100 μm (Cahill et al., 1996). On the day of use, the electrode was soaked
for 10 minutes in isopropanol purified with activated carbon (Bath et al., 2000). To make
contact with the carbon fiber, a potassium acetate solution was injected into the glass
capillary and a silver wire was inserted into the open end of the capillary and twisted to
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ensure solid contact with the carbon fiber. The reference electrode was chloridized by
placing a silver wire in a HCl solution and applying +5 V.
Fast-scan cyclic voltammetry was used in all experiments. The potential of the working
electrode was held at -0.4 V vs Ag/AgCl between scans and was ramped to +1.3 V at 400 V/
s and repeated at a frequency of 10 Hz. All cyclic voltammograms were background
subtracted using a voltammogram obtained immediately before the concentration change
evoked by the stimulation. Voltammograms were correlated with authentic dopamine signals
as described previously (Troyer et al., 2002). After the experiment the working electrode
was calibrated in vitro using dopamine solutions of known concentration (Cahill et al.,
1996).
Electrical stimulation
An untwisted bipolar stimulating electrode (Plastics One, Roanoke, VA) was used to
stimulate dopaminergic neurons. The stimulus was delivered via a stimulus isolator (A-M
Systems, Sequim, WA). The stimulation train consisted of biphasic pulses (± 300 μA, 2 ms/
phase). The frequency and number of pulses per train were varied as noted in the text. The
pulses were generated by a computer and applied between the cyclic voltammograms to
avoid electrical interference.
The position of the stimulating electrode in the MFB was optimized in the following way. A
carbon-fiber microelectrode was placed in the caudate-putamen (AP +1.2, ML +2.0, and DV
-4.5, all stereotaxic coordinates in mm according to a stereotaxic atlas (Paxinos and Watson,
1986)). The stimulating electrode was lowered in a series of 100 μm increments from a hole
in the skull (AP -1.8, ML +2.0) toward the MFB. An electrical stimulation was delivered at
each location until dopamine release was measured in the caudate-putamen, typically at a
depth of 8 mm. Once a robust dopamine signal was obtained with cyclic voltammetry, the
stimulating electrode remained in place. The carbon-fiber microelectrode was further
lowered to the nucleus accumbens core to ensure that dopamine release was evoked in that
region. Next, the carbon-fiber microelectrode was removed and reinserted into a hole drilled
over the VTA (AP -5.2, ML +1.0). For the mapping studies, the electrode was lowered to the
VTA while stimulations were made in the MFB to map out the events as a function of depth.
For experiments involving the pharmacology and physiology of VTA release, the electrode
was lowered to 8 mm below the surface of the skull, the depth of the VTA.
Immunohistochemistry
Six rats were anesthesized with urethane (1.5 g/kg, i.p.) and perfused transcardially with 80
ml of 0.9% saline, followed by 80 ml of 4% paraformaldehyde. The brains were removed
immediately after fixation and post-fixed for one hour in 4% paraformaldehyde. After one
hour, the brains were transferred to phosphate buffered saline (pH 7.4) and kept in the
refrigerator overnight. The brains were then cut on a microtome into 200 μm slices and
collected in artificial cerebral spinal fluid. The slices were transferred to a pre-blocking
solution containing 10 mL of PBS at pH 7.4, 0.1 g of bovine serum albumin (BSA), 1.0 mL
of normal goat serum, and 30 μL of Triton-X 100 and allowed to incubate for 2 hours. The
slices were then incubated in a solution of primary tyrosine hydroxylase (TH) antibody
(rabbit anti-TH polyclonal, Chemicon cat# AB 152) or (rabbit anti-serotonin polyclonal,
Invitrogen, Carlsbad, CA) at a concentration of 1:200. The slices were then kept on a shaker
plate overnight at 4°C. The primary antibody was rinsed off with six aliquots of PBS at pH
7.4 for one hour. The slices were then incubated in a solution of secondary antibody
(Invitrogen Alexa Fluor(R) 555 goat/anti-rabbit) at a concentration of 1:200 for 24 hours on
a shaker plate at 4°C. The secondary antibody was rinsed off with six aliquots of PBS at pH
7.4 for one hour. The slides were mounted on glass slides using BioRad Fluoroguard
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Antifade Reagent mounting media and analyzed on a Leica SP2 Laser Scanning Confocal
Microscope (Leica Microsystems Inc., Bannockburn, IL).
The specificity of the serotonin antibody was evaluated in the dorsal raphe nucleus that has a
high concentration of serotonin (Michelsen et al., 2007). Fluorescent labeling, demonstrated
regionally specific labeling of the serotonin cell bodies in the dorsal raphe nucleus (data not
shown).
High performance liquid chromatography (HPLC)
Tissue samples were dissected from brain slices containing the area of interest (500 μm
thickness). The tissue was wet weighted in a pre-tared volume of extraction solution of 200
μL 0.1 N HClO4 spiked with 1 μM hydroquinone (HQ). The tissue was homogenized with a
sonic dismembrator (Fisher Sci., Model 60, Pittsburgh, PA, USA). The homogenized tissue
was centrifuged at 6000 rpm for 10 min, and the supernatant was removed and filtered using
a 0.2-μm syringe microfilter (Millex-LG). Injections (10 μL) were made onto a reverse
phase column (C-18, 5 μm, 4.8 × 250 mm, Waters symmetry 300). The mobile phase
(prepared in HPLC grade water) contained 0.1 M citric acid, 1 mM hexyl sodium sulfate, 0.1
mm EDTA, and 10% methanol (pH 3.5) at a flow rate of 1 mL/min. Catecholamines were
detected with a thin-layer radial electrochemical flowcell (BASi, West Lafayette, IN, USA)
at a potential of 700 mV versus a Ag/AgCl reference electrode. Catecholamine standards
were prepared from 10 mM stock solutions in 0.1 N perchloric acid. A labview stripchart
recorder program (Jorgenson Lab, UNCCH) was used for data collection through home-built
electronic equipment.
Data analysis
The shape of the stimulated release and uptake curve was evaluated with a simple kinetic
model (Wightman et al., 1988) using nonlinear regression (Wu et al., 2001). Each stimulus
pulse was considered to release a fixed amount of dopamine, and in the time between pulses
and after the stimulus train uptake was assumed to follow Michaelis-Menten kinetics
characterized by a Vmax and a Km. Since all of the uptake inhibitors that were used are
competitive, changes in the Km value following their administration were determined. Data
were evaluated in Graph Pad Prism (Graph Pad Software, San Diego, CA) and are expressed
as mean ± SEM. Statistical significance was determined using a two-way ANOVA, and
posthoc comparisons were performed using the method of least squares with a Bonferroni
correction.
HPLC data analysis was performed using custom Igor programs for baseline correction and
peak area analysis (Jorgenson Lab, UNC-CH). The peak area of the analyte was divided by
the peak area of the internal standard HQ which is present in the extraction buffer at a
known concentration. After correction for differential detector response, the amount of
analyte in the brain tissue could be calculated.
Chemicals and solutions
All chemicals and drugs were purchased from Sigma/Aldrich (St. Louis, MO) and used as
received. Solutions were prepared using doubly distilled deionized water (Megapure system,
Corning, NY). The TRIS buffer solution for flow cell analysis was prepared using 12 mM
TRIS, 140 mM NaCl, 3.2 mM KCl, 1.2 mM CaCl2, 1.25mM NaH2PO4, 1.2 mM MgCl2, 2.0
mM Na2SO4 at pH 7.4. All drugs were dissolved in physiological saline and injected
intraperitoneally. To aid in dissolution, nomifensine was prepared by adding small amounts
of tartaric acid to the saline solution as described previously (Garris et al., 2003).
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Detection of dopamine release in the VTA
The stimulating electrode was positioned in the MFB at a site where it could elicit robust
dopamine release in the nucleus accumbens core as measured with a carbon-fiber
microelectrode (Garris and Wightman, 1994; Kuhr et al., 1986). Then, the carbon-fiber
microelectrode was extracted from the brain and placed above the VTA. It was lowered
towards the VTA in 200 μm increments (Fig. 1a, dashed line). At each location, the MFB
was stimulated with a pulse train of 60 biphasic, 300 μA electrical pulses delivered at 60 Hz.
The maximal response in the background-subtracted voltammogram at 0.6 V (the potential
where dopamine is oxidized) observed during stimulation was normalized to the maximal
response observed on the whole track, and plotted as a function of electrode depth (Fig. 1b).
Between 4 and 6 mm along the track, the stimulation evoked little release. An electroactive
substance was evoked at depths of 6.0 - 8.0 mm, regions that correlate approximately to the
location of the interstitial medial longitudinal fasciculus (iMLF), a subregion of the
thalamus, and the red nucleus that lies below it. However, the cyclic voltammograms in
these regions showed a poor match for dopamine (example in Fig. 1c, middle panel, r2 =
0.541 for comparison of a cyclic voltammogram measured in this region to a cyclic
voltammogram obtained during stimulated release in the nucleus accumbens core). At
depths of between 8 and 9 mm, the coordinates of the VTA, release of an electrochemically
active substance was also elicited. At these depths, the background-subtracted cyclic
voltammograms had an oxidation peak at +0.6 V, and a reduction peak at -0.2 V (example in
Fig. 1c, right panel), identical to that expected for a catecholamine (Heien et al., 2003).
These cyclic voltammograms showed a high correlation with the cyclic voltammograms for
dopamine recorded in the nucleus accumbens core (r2 = 0.916 for the cyclic voltammogram
recorded in the VTA compared to one obtained in the nucleus accumbens core).
Dopamine distribution in the midbrain
To evaluate whether the voltammetric signals obtained at various depths were coincident
with dopaminergic neurons, TH localization was examined with immunohistochemistry. A
secondary antibody conjugated to a fluorescent marker, Alexa-555/anti-rabbit, was used to
visualize TH localization. The region indicated by the white box in Figure 2a shows the area
examined by the confocal image in Figure 2b. The image shows TH antibody binding only
in the region ventral to 8 mm, the VTA. In this region, the fluorescence TH antibody binding
can be seen in cell bodies surrounded by wispy projections, likely corresponding to
dendrites (Fig. 2b). When the confocal image (Fig. 2b) was correlated with the
electrochemical depth profile (Fig. 1b), it is clear that release with a signature dopamine
cyclic voltammogram occurs where TH antibody binding is localized, below 8 mm, but not
in the more dorsal regions where another electroactive species is observed.
To examine whether serotonin could contribute to the measured signal, additional
immunohistochemical experiments were done with a rabbit/anti serotonin primary antibody.
Again, the Alexa-555 conjugated goat/anti-rabbit secondary antibody was used to visualize
the serotonin antibody binding with fluorescence. The region that contains the red nucleus is
shown by the dashed black square in Fig. 2a, and it displayed strong fluorescence due to the
antibody labeling with a roughly circular shape corresponding to the red nucleus (Fig. 2c).
In this image, the midline is located at the left edge of the image, and the VTA and SN are
located along the lower edge of the image. Both dopaminergic cell body regions showed
weaker, but measurable, serotonin reactivity. No fluorescent labeling was apparent in the
iMLF (Fig. 2d, black square from Fig. 2a). The midline and ventricle are located on the left
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edge of this image, and possess only faint labeling; however, the region containing the iMLF
is almost black.
To determine the amount of electroactive neurotransmitters in the VTA and the more dorsal
regions, we dissected these regions and analyzed their content by liquid chromatography
with electrochemical detection. The dissected tissue was sonicated in perchloric acid to
liberate small molecule neurotransmitters from the tissue. Neurotransmitter amounts were
obtained by ratioing the peak areas with hydroquinone that was used as an internal standard.
In the VTA, dopamine and serotonin were detected (Table I) while epinephrine and
norepinephrine levels were below detection limits. However, in the more dorsal region,
which includes the red nucleus, serotonin was observed but dopamine was not.
Pharmacological characterization in the VTA
The remaining experiments were conducted in the VTA (histological marking of the carbon-
fiber sites is given by the black dots in Figure 1a) where all of the evidence indicates
dopamine is the species released. Dopamine release was evoked by electrical stimulation (60
pulse, 60 Hz, 300 μA) delivered at three-minute intervals, and, once stable release was
obtained, the effects of various pharmacological agents on this signal were examined. As
seen in Figure 3b, the maximal amplitude of stimulated release is very reproducible both
before and after saline. The maximal release of dopamine in the VTA with this stimulation
corresponded to ~150 nM, which is significantly less than the 1 μM commonly seen in the
nucleus accumbens core with less intense stimulation parameters (Heien et al., 2005). The
Vmax (0.13 ± 0.03 μM/s) was in the range reported previously in brain slices containing the
VTA, 0.15 μM/s (John et al., 2006).
Cocaine can inhibit uptake of serotonin, norepinephrine, and dopamine (Iversen, 2006). At a
dose of 20 mg/kg, cocaine dramatically inhibits dopamine uptake in the nucleus accumbens
(Suaud-Chagny et al., 1995). Using a slightly higher dose (30 mg/kg i.p.), cocaine
significantly increased the amplitude of neurotransmitter released, as well as inhibited the
clearance. The apparent value of Km increased 820% ± 110% (n = 7, p < 0.01)
(representative trace in Fig. 3a). Twenty minutes after administration of cocaine, maximal
release was increased approximately three-fold (n = 7, p < 0.007) (Fig. 3b).
Nomifensine selectively inhibits uptake by catecholamine transporters (Lengyel et al.,
2008). At a dose of 20 mg/kg, nomifensine inhibits dopamine uptake in the NAc (Suaud-
Chagny et al., 1995). Using this dose, stimulated release in the VTA was increased by 250%
(n = 5, p < 0.004) and the apparent value of Km was increased 610% ± 140 (n = 5, p < 0.05)
(Fig. 3b). The increase in release following nomifensine persisted for approximately 40
minutes; and the effects of the drug wore off approximately 2 hours after administration
(data not shown).
The effect of a selective uptake blocker of the serotonin transporter, citalopram, was also
examined. At a dose of 5 mg/kg i.p., citalopram has been shown to increase extracellular
serotonin concentrations in the NAc (Weikop et al., 2007). Increasing the dose four-fold to
20 mg/kg was insufficient to affect the concentration of evoked neurotransmitter in the VTA
(Fig. 3b), even though a 20 mg/kg injection of nomifensine 30 minutes later in the same
animal was able to increase release (Fig. 3c, p < 0.009). Desipramine, a selective
norepinephrine transport inhibitor, has been shown to increase stimulated norepinephrine
release by as much as 200% in the NAc (Brun et al., 1993) at a dose of 10 mg/kg i.p. Using
a higher dose of 20 mg/kg produced no significant change in the VTA (Fig. 3b). Application
of a 20 mg/kg injection of nomifensine 30 minutes after administration of desipramine at the
same location increased the maximal release by approximately 225% (Fig. 3c, p < 0.01).
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The subsequent application of nomifensine verifies that uptake control was present at the
site being recorded.
In the NAc, dopamine release can be modulated by drugs that interact with autoreceptors.
Specifically, the D2 autoreceptor agonist, quinpirole, and the D2 autoreceptor antagonist,
raclopride, decrease and increase, respectively, the maximum evoked dopamine release in
the NAc (Cragg and Greenfield, 1997). Intraperitoneal injections of either the agonist,
quinpirole or the antagonist, raclopride (both at 1 mg/kg) were given, and the amplitude of
release was then measured in the VTA 20 minutes after administration of the drug. There
was no significant change in the signal in the VTA upon administration of either drug (Fig.
3b). These data suggest that dopamine release was not under autoregulation by the dopamine
D2 autoreceptor, consistent with prior reports (Cragg and Greenfield, 1997).
Physiological characterization
To probe the characteristics of release in the VTA, the frequency of electrical stimulation
was varied (Fig. 4). During stimulation, the overflow of dopamine in terminal regions shows
a frequency dependent behavior (Wightman et al., 1988;Wu et al., 2001), where the
temporal changes in extracellular dopamine concentration can be described by the release of
dopamine minus the amount cleared via uptake that follows Michaelis-Menten kinetics.
Thus, high stimulation frequencies should lead to greater amounts of release than lower
frequencies. A plot of dopamine concentration versus stimulation frequency (Fig. 4d)
revealed such a relationship. The approximately linear relationship between release
amplitude and stimulation frequency are consistent with dopamine release seen at the
terminals of dopaminergic neurons (Garris and Wightman, 1994). The shape of release at 10
Hz (Fig. 4a) approaches a steady state indicating that the release and uptake components are
balanced at this frequency. The release profile at 50 Hz increases during the stimulation,
demonstrating that release overwhelms uptake at this frequency (Fig. 4c). The slower
dopamine uptake is consistent with measurements performed in VTA brain slices (John et
al., 2006).
To probe the effect of extended stimulation, dopamine release was measured during a 50 s
electrical stimulation (60 Hz). The amplitude of release rose until approximately 5 seconds
after the initiation of stimulation. After this, overflow actually diminished, even though the
stimulation was maintained, demonstrating depletion of the neurotransmitter available for
release (Fig. 5a). A second identical stimulation train immediately following the completion
of the depletion stimulation led to a marked decrease in amplitude when compared to the
first stimulation (Fig. 5b). These depletion results are consistent with the long-lasting
depression observed previously in the caudate-putamen (Montague et al., 2004;Nicolaysen
et al., 1988).
DISCUSSION
The release of dopamine in the VTA has been well documented to occur with local electrical
stimulation in brain slices (Chen and Rice, 2002; Cragg and Greenfield, 1997; John et al.,
2006; Rice et al., 1997). The goal of this work was to evaluate the effect of backward-
propagating action potentials on the somatodendritic release of dopamine in the VTA of an
intact, anesthetized animal. Electrophysiological studies have provided evidence that
stimulations can propagate through the axon and should evoke dendritic release (Gentet and
Williams, 2007; Hausser et al., 1995). To this end, the stimulating electrode was placed in
the MFB more than 3 mm away from the VTA and at a site that elicited release in terminal
regions. Robust catecholamine release was observed in the VTA, and chromatographic
analysis of the tissue established that dopamine was the only catecholamine present in this
region that could contribute to the voltammetric signal. Subsequent pharmacological studies
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established that dopamine release in this region is counterbalanced by uptake, and it was
unaffected by agents that lacked pharmacological activity at the dopamine transporter.
Release was found to be similar to that in terminal regions in most respects. Overflow of
dopamine increased with increasing frequency. Furthermore, the amount of dopamine
available for release was limited (Figure 5), a behavior also seen in striatal terminal regions
(Garris et al., 1993), because only a portion of dopamine stores reside in releasable pools.
Release differed from that in striatal regions in that it was insensitive to autoreceptor
regulation, a feature also observed in slices of the VTA (Cragg and Greenfield, 1997).
Otherwise, the data show that dopamine released from somatodendritic sources in the VTA
undergoes similar regulation as found in terminal striatal regions.
The strategy used in this work to evoke release of dopamine in the VTA has been used to
map release in terminal regions previously (Garris et al., 1993; Stamford et al., 1988).
Electrical stimulation of the MFB of an anesthetized animal elicits release in a wide range of
dopamine terminal regions. We anticipated that electrical stimulations of the MFB would
also elicit release from dopamine cell bodies because stimulation pulses have been shown to
back propagate to dopamine cell bodies (Kuhr et al., 1987). Furthermore, at dopamine
neurons in the SN, the axon emerges from a dendrite (Hausser et al., 1995). Because of this
arrangement, action potentials generated in the axons show little attenuation in the dendritic
tree (Gentet and Williams, 2007), and should cause exocytotic release. Consistent with these
expectations, MFB stimulations were sufficient to evoke dopamine release in the VTA,
suggesting that these neurons have similar architecture. However, we did not anticipate the
evoked electrochemical responses at locations dorsal to the VTA. Was this dopamine
released in the VTA that diffused to more dorsal locations? Alternatively, was it release of
other substances from local terminals that were activated by the MFB stimulation? The
voltammetric signals in the regions dorsal to 8 mm were insufficient to identify the
measured substance(s) because of poor signal to noise. All catecholamines have a similar
signature with fast-scan cyclic voltammetry, and the cyclic voltammogram for serotonin
only differs from catecholamines in that its reverse wave is at more positive potentials
(Heien et al., 2003; John et al., 2006).
To provide further evidence to support the voltammetric identity of dopamine release in the
VTA, we used antibody binding for TH and chromatographic analysis of tissue content of
the mesencephalic subregions probed during the descent of the electrode to the VTA. As
expected from prior histochemistry for dopamine (Bjorklund and Lindvall, 1975), the VTA
was clearly stained with antibodies to TH, however, TH was not seen in the region
immediately dorsal to the VTA, the red nucleus In contrast, an antibody to serotonin showed
considerable binding in the red nucleus with weaker, but observable, binding in the VTA.
Consistent with our chromatographic findings, the red nucleus has been shown to contain
significant amounts of serotonin (Palkovits et al., 1974) and it receives serotonergic
innervation through the MFB (Pierce et al., 1976), suggesting a possible mechanism for its
release with our protocol. Although dopamine was the predominant electroactive species
found in the VTA, serotonin was also present, consistent with the documented serotonin
receptors (Liu et al., 2006) and releasable serotonin (Yan et al., 2005) found there. The
voltammetric recordings, however, showed no evidence for concurrent serotonin release.
Thus, if the stimulation evoked serotonin releases, its concentration was much less than
dopamine, and its presence was masked. No binding of the serotonin antibody was evident
in the iMLF although there was weak labeling for TH (data not shown). Thus, a
catecholamine may have contributed to the voltammetric signal evoked by stimulation in
that region.
In brain slices, dopamine uptake in the VTA has been reported to follow Michaelis-Menten
kinetics with a similar Km as found in terminal regions. However, Vmax values in striatal
Kita et al. Page 8













areas are ~30 times greater than those in the VTA (John et al., 2006). Our results show that
the uptake of dopamine in the VTA is by the dopamine transporter because it was inhibited
with agents that inhibit the dopamine transporter (cocaine, nomifensine), but it was
unaffected by agents specific for inhibition of the serotonin (citalopram) or norepinephrine
(desipramine) transporters. These results are in agreement with prior measurements in slices
(John and Jones, 2007). Diffusion of dopamine from the site of release to other sites can
occur with slow uptake as in the VTA. This so-called volume transmission (Garris and
Rebec, 2002) is proportional to the square root of the residence time of dopamine in the
extracellular space. Even though this time may be 30 times longer than in striatal regions,
we would anticipate diffusion distances of less than 30 μm based on these rates. Thus,
diffusion distances are much less than the 100's of microns needed for VTA dopamine to
diffuse to the red nucleus and IMLF and contribute to the signals measured in those regions.
However, despite the fact that dopamine can diffuse in the VTA, its actions on cells are
short-lived indicating that proximal interactions are important as well (Beckstead et al.,
2004).
In terminal regions, electrically evoked dopamine release is under control of autoreceptors
that can be blocked by raclopride (Cragg and Greenfield, 1997; Kita et al., 2007). Such
regulation was not found for dopamine VTA release in the intact animal, consistent with
findings in brain slices (Beckstead et al., 2007; Cragg and Greenfield, 1997). This is a rather
surprising result since D2 receptors on the dendrites of dopaminergic neurons are present
and regulate cell firing (Lacey et al., 1987). It may be that the hyperpolarization
accompanying D2 receptor activation (Lacey et al., 1987) is simply overcome by the
electrical stimulation. However, regulation of cell firing would also regulate dopamine
release under physiological conditions without directly inhibiting it.
When examined in brain slices, electrically evoked somatodendritic release of dopamine
shows a maximum at 10 Hz (Rice et al., 1997). A quite different response is obtained in vivo
(Figure 4) with evoked release continuing to increase up to 60 Hz, a frequency dependence
that is similar to that found in terminal regions (Garris et al., 1993). Indeed, the short term
plasticity characterized in brain slices (Beckstead et al., 2007) simply is not present in the
intact brain. Similar differences have been reported in terminal regions when release in vivo
and in brain slices are compared (Kennedy et al., 1992), although the origins are not
understood. One suggestion for the differences found between brain slices and in vivo may
be due to a lack of endogenous tone in the former preparation where inputs have been
severed. The results of this study clearly show that, when in vivo results are compared,
somatodendritic and terminal release of dopamine are quite similar, including the restricted
amount of dopamine available for stimulated release.
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Location of carbon-fiber electrode in the midbrain. The position of the carbon-fiber
electrode was determined by lowering it through the midbrain with a stereotaxic
micromanipulator, while the stimulating electrode was in the MFB. Signals were recorded in
the midbrain during a 60 Hz, 60 p, 300 μA electrical stimulation of the MFB. (a) Brain slice
obtained -5.20 mm posterior from bregma. Black squares indicate final position of four of
the electrodes determined histologically. The areas under investigation include the iMLF,
RN and the VTA. Regions labeled in the left hemisphere are structurally identical to the
regions in the right hemisphere. The dashed line represents the track of the working
electrode, and the solid lines represent the depth of the VTA. (b) The normalized
concentration of evoked neurotransmitter (NT) was measured in 200 μm increments as the
working electrode was lowered. In each animal, the signal at each data point was normalized
to the maximum amplitude of release obtained from the animal. (n = 6) (c) Representative
cyclic voltammograms obtained from the NAc (left panel) and depths of 7.6 mm (middle
panel) and 8.8 mm (right panel). R2 values correspond to the correlation between CV's from
midbrain and the dopamine CV obtained from the NAc.
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Dopaminergic structures in the ventral tegmental area (VTA). To identify dopamine
innervation in the midbrain, TH was labeled with a primary antibody (rabbit/anti-TH). A
fluorescent secondary antibody, Alexa-555/anti-rabbit, was used to provide a marker for TH.
(a) Brain slice from the midbrain used to orient regions displayed in immunohistochemical
images. White square corresponds to panel (b), the dashed square to panel (c), and the dark
bordered square to panel (d). (b) A 10X fluorescent image showing the white fluorescent
labeling of TH in the right hemisphere of the VTA. The bright dots indicate cell bodies
(white arrows). (c) A 10X fluorescent image of the RN following labeling with an antibody
to serotonin. Serotonin labeling is shown in white. (d) A 10X fluorescent image of the iMLF
following labeling with an antibody to serotonin.
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Effect of uptake inhibitors and D2 agents on evoked release in the VTA. Release was
evoked via a 60 Hz, 60 p, 300 μA electrical stimulation of the MFB. Signals were recorded
in the VTA before and after administration of saline, cocaine (n = 7, 30 mg/kg i.p.),
nomifensine (nomi, n = 5, 20 mg/kg i.p.), citalopram (citalo, n = 5, 20 mg/kg i.p.),
desipramine (desi, n = 5, 20 mg/kg i.p.), raclopride (raclo, n = 5, 1 mg/kg i.p.), and
quinpirole (quin, n = 5, 1 mg/kg i.p.). (a) Representative trace of dopamine release before
and after administration of cocaine. (b) Saline injection had no significant effect. Cocaine
administration significantly increased the signal by 300% (p < 0.007). Administration of
nomifensine significantly increased the signal by 250% (p < 0.004). The selective serotonin
reuptake inhibitor, citalopram, had no significant effect. The selective norepinephrine
reuptake inhibitor, desipramine, had no effect. (c) Nomifensine administered 30 minutes
after either citalopram (n = 5, p < 0.009) or desipramine (n = 5, p < 0.01) in the same rat
significantly increased the signal.
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Effect of stimulation frequency on signal amplitude in the VTA. Representative traces
obtained for a 60 p, 300 μA stimulation at (a) 10 Hz, (b) 30 Hz, (c) 50 Hz. (d) The effect of
stimulation frequency can be seen with [DA] (μM) plotted as a function of the stimulation
frequency (Hz).
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Effect of prolonged stimulation on electrically evoked dopamine release. Dopamine release
was evoked by a 60 Hz, 3000 p, 300 μA electrical stimulation. (a) Representative trace of
two identical stimulations. During the first stimulation dopamine release reached a steady
state within 5 seconds and slowly returned to baseline over the course of 50 seconds. The
second identical stimulation event occurred 10 seconds after the completion of the first
stimulation. (c) The amplitude of dopamine release after 5 s of stimulation is significantly
less during the second stimulation (n = 5, p < 0.03)
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Table I
Neurotransmitter content obtained from the VTA and RN by HPLC. The content of both dopamine and
serotonin was obtained by dissecting brain tissue from the RN and VTA and analyzing the supernatant from
the homogenized tissue using HPLC. Norepinephrine and epinephrine were not detectable in either region.
Brain Region Dopamine (μg/g) Serotonin (μg/g)
RN ND 0.69 ± 0.01
VTA 1.26 ± 0.08 0.86 ± 0.08
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